BOSTON (April 29, 2011) – A gene therapy approach using a protein called CD59, or protectin, shows promise in slowing the signs of age-related macular degeneration (AMD), according to a new in vivo study by researchers at Tufts University School of Med…
Month: April 2011
CATT Study Update 14: One-Year Study Results Show Equivalency Between Avastin and Lucentis
The Comparison of AMD Treatment Trials (CATT Study) one-year results were released today in the New England Journal of Medicine (NEJM). As anticipated, the two anti-VEGF drugs, Avastin and Lucentis, both produced by Genentech, showed equivalent results…
Lucentis And Avastin Equally Effective For AMD – Avastin Results In More Hospitalizations
Lucentis and Avastin, both made by pharmaceutical company Genentech, were found to be equally effective in treating age-related macular degeneration (AMD). Lucentis is approved for this eye-condition, while Avastin, a cancer medication, is also used of…
Anti-VEGF Drug Trial Results in AMD Released Early (CME/CE)
(MedPage Today) — Full publication of results from the head-to-head study of bevacizumab (Avastin) and ranibizumab (Lucentis) in “wet” age-related macular degeneration has confirmed information previously leaked to the media — that the two drugs diff…
Medicare Quality Bonuses More Than Doubled in 2010
However, the incentive program turns into a penalty program in 2015 for physicians who fail to report their performance on quality measures. Medscape Medical News
Merck, Inspire announce expiration of HSR waiting period for cash tender offer
Merck, known as MSD outside the United States and Canada, and Inspire Pharmaceuticals, Inc. today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR”) has expired in connection with the pr…
Molecular Partners Reports Positive Results From Its First Clinical Studies
Molecular Partners AG, a leader in the development of next generation therapeutics, announced today that it has completed two phase I/IIa clinical trials with MP0112, its lead molecule targeting VEGF-A. The DARPin molecule was shown to be safe and well…
Cleveland Clinic-Led Study Finds Bevacizumab As Effective As FDA-Approved Ranibizumab In Treating Macular Degeneration
A new study published online today in The New England Journal of Medicine (NEJM) shows bevacizumab (Avastin) is as effective as ranibizumab (Lucentis), the current Food and Drug Administration-approved drug for treating age-related macular degeneration…
Molecular Partners completes MP0112 phase I/IIa trials in wet AMD, DME
Molecular Partners AG, a leader in the development of next generation therapeutics, announced today that it has completed two phase I/IIa clinical trials with MP0112, its lead molecule targeting VEGF-A.
There’s More To Implants Than Meets The Eye
In this month’s Physics World, Richard Taylor, professor of physics, psychology and art at the University of Oregon, warns that artificial retinal implants – a technology fast becoming a reality – must adapt to the unique features of the human eye in o…
Regeneron And Bayer Report Positive Results For VEGF Trap-Eye In Second Phase 3 Study In Central Retinal Vein Occlusion
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer HealthCare announced positive top-line results for VEGF Trap-Eye (aflibercept ophthalmic solution) in the Phase 3 GALILEO study in patients with macular edema due to central retinal vein occlusio…
STAAR Surgical’s NanoFLEX™ Collamer® IOL Receives CE Mark Approval
STAAR Surgical Company , a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today announced CE Mark approval for its nanoFLEXT Collamer® Single Piece IOL which can be injected through a 2.2 mm incision with the n…
STAAR Surgical’s NanoFLEX™ Collamer® IOL Receives CE Mark Approval
STAAR Surgical Company , a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today announced CE Mark approval for its nanoFLEXT Collamer® Single Piece IOL which can be injected through a 2.2 mm incision with the n…
NIH Study Finds Avastin And Lucentis Are Equally Effective In Treating Age-Related Macular Degeneration
Researchers are reporting results from the first year of a two-year clinical trial that Avastin, a drug approved to treat some cancers and that is commonly used off-label to treat age-related macular degeneration (AMD), is as effective as the Food and …
No Difference In Anti-VEGF Drugs For Wet AMD
Researchers conducting a closely watched head-to-head study of intravitreal bevacizumab (Avastin) and ranibizumab (Lucentis) for slowing “wet” age-related macular degeneration (AMD) will report that the drugs were equally effective, according t…
Hyperopic LASIK May Increase Epithelial Ingrowth More Than Myopic LASIK
Patients undergoing hyperopic LASIK had an increased incidence of epithelial ingrowth compared with patients undergoing myopic LASIK, a study found.
Sequenom Announces Publication Acceptance Of Manuscript From Age-Related Macular Degeneration Validation Study
Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced the acceptance for publication of the manuscript, “Clinical Validation of a Genetic Model to Estimate the Risk of Developing Choroid…
No Difference in Anti-VEGF Drugs for Wet AMD
(MedPage Today) — Researchers conducting a closely watched head-to-head study of intravitreal bevacizumab (Avastin) and ranibizumab (Lucentis) for slowing “wet” age-related macular degeneration (AMD) will report that the drugs were equally effective, …
CATT Study Update 13: A First Peek
As reported by Andrew Pollack of the NYTimes, in a column published earlier today, the first results of the 1200 patient CATT Study (Comparison of AMD Treatments Trials), whose first-year results are scheduled for release at ARVO on Sunday afternoon, i…
Laser and anti-VEGF Best Treats Diabetic Macular Edema
A new study finds the combination of laser treatment with intraocular injections of anti-VEGF to be the best treatment for diabetic retinopathy.